Limits...
Prevalence of Human Papillomavirus Genotypes Among Women With High-Grade Cervical Lesions in Beijing, China

View Article: PubMed Central - PubMed

ABSTRACT

The aim of the study is to investigate the prevalence of high-risk human papillomavirus (hr-HPV) genotypes among Han women with high-grade cervical lesions in Beijing, China.

Cervical cell specimens from patients with histopathologically confirmed cervical lesions at 7 hospitals in Beijing were examined with a validated HPV kit for 13 hr-HPV genotypes during the study period. The patients were divided into a low-grade cervical lesions group (cervical intraepithelial neoplasia grade 1, CIN1) and a high-grade cervical lesions group (CIN2+, including cervical intraepithelial neoplasia grade 2, CIN2; cervical intraepithelial neoplasia grade 3, CIN3; squamous cervical cancer, SCC; and adenocarcinoma of the cervix, ACC) based on the histopathology results.

A total of 2817 eligible patients were enrolled, including 610 cases identified as CIN1 and 2207 as CIN2+. The hr-HPV positive rates in the CIN1 and CIN2+ groups were 78.2% (477/610) and 93.3% (2060/2207), respectively. The most frequently detected genotypes were HPV16, 58, 52 and18 in the CIN1 group and HPV16, 58, 33, and 52 in the CIN2+ group, in descending order of prevalence. In addition, the prevalence of HPV18 among the patients with ACC was 28.6% (14/49), significantly >7.2% (54/752) prevalence among the SCC patients (P < 0.001). Additionally, significantly more women in the CIN2+ group had multiple infections compared with those in the CIN1 group (38.1% and 24.9%, respectively; P < 0.001). However, as the cervical lesion grade increased, the prevalence of multiple hr-HPV infections gradually deceased to 44.2% in the CIN2 patients, 36.7% in the CIN3 patients, and 35.3% in the cervical cancer (CC) patients, which included SCC and ACC patients. In cases of multiple hr-HPV infections in the CIN2+ group, double infections accounted for ∼76.6%, and HPV16+58, HPV16+52, and HPV16+18 were the most common combinations, in descending order. The most frequent combination for triple infections was HPV16+58+31, with a rate of 4.2%. The highest positive rate occurred in the ≤24 year-old group for all types of cervical lesions.

The prevalence of HPV genotypes in the targeted population with high-grade cervical lesions differs from that of other countries. This information could be helpful for the prevention of CC in Beijing, China.

No MeSH data available.


Related in: MedlinePlus

(A) Prevalence of high-risk human papillomavirus (hr-HPV) by age group in CIN1 (cervical intraepithelial neoplasia grade 1) and CIN2+ (high-grade cervical lesions, including cervical intraepithelial neoplasia grade 2 [CIN2], cervical intraepithelial neoplasia grade 3 [CIN3], squamous cervical cancer [SCC], and adenocarcinoma of the cervix [ACC]) patients; (B) age-specific distributions of hr-HPV genotypes in CIN2+ patients; (C) age-specific distributions of hr-HPV genotypes in CIN2 patients; (D) age-specific distributions of hr-HPV genotypes in CIN3 patients; (E) age-specific distributions of hr-HPV genotypes in SCC patients; (F) age-specific distributions of hr-HPV genotypes in ACC patients. ACC = adenocarcinoma of the cervix, CC = cervical cancer, CIN2 = cervical intraepithelial neoplasia grade 2, CIN2+ = (high-grade cervical lesions, including CIN2, CIN3, SCC, and ACC) patients, CIN3 = cervical intraepithelial neoplasia grade 3, hr-HPV = high-risk human papillomavirus, SCC = squamous cervical cancer.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4998280&req=5

Figure 3: (A) Prevalence of high-risk human papillomavirus (hr-HPV) by age group in CIN1 (cervical intraepithelial neoplasia grade 1) and CIN2+ (high-grade cervical lesions, including cervical intraepithelial neoplasia grade 2 [CIN2], cervical intraepithelial neoplasia grade 3 [CIN3], squamous cervical cancer [SCC], and adenocarcinoma of the cervix [ACC]) patients; (B) age-specific distributions of hr-HPV genotypes in CIN2+ patients; (C) age-specific distributions of hr-HPV genotypes in CIN2 patients; (D) age-specific distributions of hr-HPV genotypes in CIN3 patients; (E) age-specific distributions of hr-HPV genotypes in SCC patients; (F) age-specific distributions of hr-HPV genotypes in ACC patients. ACC = adenocarcinoma of the cervix, CC = cervical cancer, CIN2 = cervical intraepithelial neoplasia grade 2, CIN2+ = (high-grade cervical lesions, including CIN2, CIN3, SCC, and ACC) patients, CIN3 = cervical intraepithelial neoplasia grade 3, hr-HPV = high-risk human papillomavirus, SCC = squamous cervical cancer.

Mentions: The hr-HPV prevalence in the CIN1 and CIN2+ groups by the age group is shown in Figure 3A, and the prevalence and distributions of hr-HPV by the age group for patients with CIN2+, CIN2, CIN3, SCC, and ACC are presented in Figures 3B, C, D, E and F, respectively. For all cervical lesion types, the highest positive rate was observed in the ≤24 year group; this age group accounted for 90.5% of the CIN1patients; 93.8% of the CIN2 patients; 100% of the CIN3, SCC, and ACC patients; and 96.2% of the CIN2+ patients. In the CIN1 group, the hr-HPV positive rate decreased gradually until it reached its lowest point at 40 to 44 years; and then gradually increased as the age increased; in contrast, the hr-HPV infection rates in patients with CIN2+ were similar for all age groups, with a peak at ≤24 years. Moreover, in the CIN2+, CIN3, and ACC groups, HPV16 was most prevalent among younger women (≤39 years); in contrast, HPV58 and HPV18 were most prevalent among women in the ≥50-year and 40- to 44-year groups. Younger women in the CIN2 and SCC groups were more prone to infections with HPV16, 18, and 58, with the highest prevalence in patients aged ≤24 years.


Prevalence of Human Papillomavirus Genotypes Among Women With High-Grade Cervical Lesions in Beijing, China
(A) Prevalence of high-risk human papillomavirus (hr-HPV) by age group in CIN1 (cervical intraepithelial neoplasia grade 1) and CIN2+ (high-grade cervical lesions, including cervical intraepithelial neoplasia grade 2 [CIN2], cervical intraepithelial neoplasia grade 3 [CIN3], squamous cervical cancer [SCC], and adenocarcinoma of the cervix [ACC]) patients; (B) age-specific distributions of hr-HPV genotypes in CIN2+ patients; (C) age-specific distributions of hr-HPV genotypes in CIN2 patients; (D) age-specific distributions of hr-HPV genotypes in CIN3 patients; (E) age-specific distributions of hr-HPV genotypes in SCC patients; (F) age-specific distributions of hr-HPV genotypes in ACC patients. ACC = adenocarcinoma of the cervix, CC = cervical cancer, CIN2 = cervical intraepithelial neoplasia grade 2, CIN2+ = (high-grade cervical lesions, including CIN2, CIN3, SCC, and ACC) patients, CIN3 = cervical intraepithelial neoplasia grade 3, hr-HPV = high-risk human papillomavirus, SCC = squamous cervical cancer.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4998280&req=5

Figure 3: (A) Prevalence of high-risk human papillomavirus (hr-HPV) by age group in CIN1 (cervical intraepithelial neoplasia grade 1) and CIN2+ (high-grade cervical lesions, including cervical intraepithelial neoplasia grade 2 [CIN2], cervical intraepithelial neoplasia grade 3 [CIN3], squamous cervical cancer [SCC], and adenocarcinoma of the cervix [ACC]) patients; (B) age-specific distributions of hr-HPV genotypes in CIN2+ patients; (C) age-specific distributions of hr-HPV genotypes in CIN2 patients; (D) age-specific distributions of hr-HPV genotypes in CIN3 patients; (E) age-specific distributions of hr-HPV genotypes in SCC patients; (F) age-specific distributions of hr-HPV genotypes in ACC patients. ACC = adenocarcinoma of the cervix, CC = cervical cancer, CIN2 = cervical intraepithelial neoplasia grade 2, CIN2+ = (high-grade cervical lesions, including CIN2, CIN3, SCC, and ACC) patients, CIN3 = cervical intraepithelial neoplasia grade 3, hr-HPV = high-risk human papillomavirus, SCC = squamous cervical cancer.
Mentions: The hr-HPV prevalence in the CIN1 and CIN2+ groups by the age group is shown in Figure 3A, and the prevalence and distributions of hr-HPV by the age group for patients with CIN2+, CIN2, CIN3, SCC, and ACC are presented in Figures 3B, C, D, E and F, respectively. For all cervical lesion types, the highest positive rate was observed in the ≤24 year group; this age group accounted for 90.5% of the CIN1patients; 93.8% of the CIN2 patients; 100% of the CIN3, SCC, and ACC patients; and 96.2% of the CIN2+ patients. In the CIN1 group, the hr-HPV positive rate decreased gradually until it reached its lowest point at 40 to 44 years; and then gradually increased as the age increased; in contrast, the hr-HPV infection rates in patients with CIN2+ were similar for all age groups, with a peak at ≤24 years. Moreover, in the CIN2+, CIN3, and ACC groups, HPV16 was most prevalent among younger women (≤39 years); in contrast, HPV58 and HPV18 were most prevalent among women in the ≥50-year and 40- to 44-year groups. Younger women in the CIN2 and SCC groups were more prone to infections with HPV16, 18, and 58, with the highest prevalence in patients aged ≤24 years.

View Article: PubMed Central - PubMed

ABSTRACT

The aim of the study is to investigate the prevalence of high-risk human papillomavirus (hr-HPV) genotypes among Han women with high-grade cervical lesions in Beijing, China.

Cervical cell specimens from patients with histopathologically confirmed cervical lesions at 7 hospitals in Beijing were examined with a validated HPV kit for 13 hr-HPV genotypes during the study period. The patients were divided into a low-grade cervical lesions group (cervical intraepithelial neoplasia grade 1, CIN1) and a high-grade cervical lesions group (CIN2+, including cervical intraepithelial neoplasia grade 2, CIN2; cervical intraepithelial neoplasia grade 3, CIN3; squamous cervical cancer, SCC; and adenocarcinoma of the cervix, ACC) based on the histopathology results.

A total of 2817 eligible patients were enrolled, including 610 cases identified as CIN1 and 2207 as CIN2+. The hr-HPV positive rates in the CIN1 and CIN2+ groups were 78.2% (477/610) and 93.3% (2060/2207), respectively. The most frequently detected genotypes were HPV16, 58, 52 and18 in the CIN1 group and HPV16, 58, 33, and 52 in the CIN2+ group, in descending order of prevalence. In addition, the prevalence of HPV18 among the patients with ACC was 28.6% (14/49), significantly >7.2% (54/752) prevalence among the SCC patients (P < 0.001). Additionally, significantly more women in the CIN2+ group had multiple infections compared with those in the CIN1 group (38.1% and 24.9%, respectively; P < 0.001). However, as the cervical lesion grade increased, the prevalence of multiple hr-HPV infections gradually deceased to 44.2% in the CIN2 patients, 36.7% in the CIN3 patients, and 35.3% in the cervical cancer (CC) patients, which included SCC and ACC patients. In cases of multiple hr-HPV infections in the CIN2+ group, double infections accounted for ∼76.6%, and HPV16+58, HPV16+52, and HPV16+18 were the most common combinations, in descending order. The most frequent combination for triple infections was HPV16+58+31, with a rate of 4.2%. The highest positive rate occurred in the ≤24 year-old group for all types of cervical lesions.

The prevalence of HPV genotypes in the targeted population with high-grade cervical lesions differs from that of other countries. This information could be helpful for the prevention of CC in Beijing, China.

No MeSH data available.


Related in: MedlinePlus